Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring
Author(s) -
Nadine Wenningmann,
Merle Knapp,
Anusha Ande,
Tanaya R. Vaidya,
Sihem AitOudhia
Publication year - 2019
Publication title -
molecular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.469
H-Index - 198
eISSN - 1521-0111
pISSN - 0026-895X
DOI - 10.1124/mol.119.115725
Subject(s) - cardiotoxicity , doxorubicin , pharmacology , oxidative stress , medicine , drug , bioinformatics , toxicity , chemotherapy , biology
Doxorubicin (DOX) is one of the most effective anticancer drugs to treat various forms of cancers; however, its therapeutic utility is severely limited by its associated cardiotoxicity. Despite the enormous amount of research conducted in this area, the exact molecular mechanisms underlying DOX toxic effects on the heart are still an area that warrants further investigations. In this study, we reviewed literature to gather the best-known molecular pathways related to DOX-induced cardiotoxicity (DIC). They include mechanisms dependent on mitochondrial dysfunction such as DOX influence on the mitochondrial electron transport chain, redox cycling, oxidative stress, calcium dysregulation, and apoptosis pathways. Furthermore, we discuss the existing strategies to prevent and/or alleviate DIC along with various techniques available for therapeutic drug monitoring (TDM) in cancer patients treated with DOX. Finally, we propose a stepwise flowchart for TDM of DOX and present our perspective at curtailing this deleterious side effect of DOX.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom